Alnylam Pharmaceuticals (NASDAQ:ALNY) Earns “Buy” Rating from Chardan Capital

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating restated by stock analysts at Chardan Capital in a report issued on Friday,Benzinga reports. They presently have a $300.00 price target on the biopharmaceutical company’s stock. Chardan Capital’s price target would indicate a potential upside of 5.88% from the stock’s current price.

A number of other brokerages have also recently issued reports on ALNY. HC Wainwright upped their price objective on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a research note on Monday, February 24th. Sanford C. Bernstein dropped their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Needham & Company LLC reiterated a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Canaccord Genuity Group increased their price target on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th. Finally, JPMorgan Chase & Co. increased their price target on Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the company a “neutral” rating in a research note on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $310.22.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $283.34 on Friday. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The stock has a 50 day simple moving average of $257.16 and a 200 day simple moving average of $259.69. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $304.39. The firm has a market capitalization of $36.68 billion, a PE ratio of -130.57 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Sell-side analysts predict that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CFO Jeffrey V. Poulton sold 967 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the sale, the chief financial officer now directly owns 32,786 shares of the company’s stock, valued at $8,366,003.62. This trade represents a 2.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CMO Pushkal Garg sold 1,548 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares in the company, valued at $3,017,271.63. This trade represents a 11.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is owned by corporate insiders.

Institutional Trading of Alnylam Pharmaceuticals

Several large investors have recently bought and sold shares of the business. Allworth Financial LP boosted its stake in Alnylam Pharmaceuticals by 6.8% in the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 38 shares in the last quarter. Investment Management Corp of Ontario boosted its stake in Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company’s stock valued at $1,670,000 after buying an additional 40 shares in the last quarter. Nixon Peabody Trust Co. boosted its stake in Alnylam Pharmaceuticals by 1.9% in the fourth quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock valued at $540,000 after buying an additional 43 shares in the last quarter. Brevan Howard Capital Management LP boosted its stake in Alnylam Pharmaceuticals by 3.4% in the fourth quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company’s stock valued at $314,000 after buying an additional 44 shares in the last quarter. Finally, IFP Advisors Inc boosted its stake in shares of Alnylam Pharmaceuticals by 24.2% during the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 47 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.